Clarity Pharmaceuticals Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
41
- Stock Symbol
-
CU6
- Share Price
-
$5.10
- (As of Friday Closing)
Clarity Pharmaceuticals General Information
Description
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.
Contact Information
Website
www.claritypharmaceuticals.comCorporate Office
- 4 Cornwallis Street
- National Innovation Centre, Suite 212a
- Eveleigh, New South Wales 2015
- Australia
Corporate Office
- 4 Cornwallis Street
- National Innovation Centre, Suite 212a
- Eveleigh, New South Wales 2015
- Australia
Clarity Pharmaceuticals Timeline
Clarity Pharmaceuticals Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.10 | $5.00 | $0.62 - $5.13 | $1.61B | 316M | 1.52M |
Clarity Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2024 30-Jun-2024 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 |
|---|---|---|---|---|
| EV | 1,097,439 | 1,097,439 | 18,181 | 26,975 |
| EBITDA | (17,656) | (17,237) | ||
| Net Income | (16,540) | (17,214) | ||
| Total Assets | 50,900 | 68,668 | ||
| Total Debt | 0 | 0 |
Clarity Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Clarity Pharmaceuticals Comparisons
Industry
Financing
Details
0000 0
000000
Clarity Pharmaceuticals Competitors (9)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bolt Biotherapeutics | Formerly VC-backed | Redwood City, CA | 000 | 00000 | 00000000 | 00000 |
| Navidea Biopharmaceuticals | Corporation | Dublin, OH | 00 | 000.00 | 0000000000. | |
| Seagen | Formerly VC-backed | Bothell, WA | 0000 | 00.000 | 000000&0 | 00.000 |
| Immatics | Formerly VC-backed | Tuebingen, Germany | 000 | 00000 | 00000000 | 00000 |
| Kazia Therapeutics | Corporation | Sydney, Australia | 0 | 000.00 | 000000000 | 000.00 |
Clarity Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Clarity Pharmaceuticals Patents
Clarity Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023903427-A0 | Cancer targeting compounds and methods for their production | Pending | 26-Oct-2023 | ||
| AU-2023902524-A0 | Methods for the diagnosis and/or treatment of prostate cancer | Pending | 09-Aug-2023 | ||
| AU-2023902019-A0 | Injectable composition for delivery of a biologically active agent | Pending | 27-Jun-2023 | ||
| AU-2023901713-A0 | Targeted dual administration cancer therapy | Pending | 31-May-2023 | ||
| AU-2023901717-A0 | Combination therapy with checkpoint inhibitors | Pending | 31-May-2023 |
Clarity Pharmaceuticals Executive Team (11)
| Name | Title | Board Seat |
|---|---|---|
| Colin Biggin Ph.D | Chief Executive Officer & Managing Director | |
| David Green | Chief Financial Officer | |
| Matthew Harris Ph.D | Chief Technology Officer & Co-Founder | |
| Chris Roberts Ph.D | Non-Executive Director | |
| Rosanne Robinson | Non-Executive Director |
Clarity Pharmaceuticals Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alan Taylor Ph.D | Clarity Pharmaceuticals | Executive Chairman | 000 0000 |
| Thomas Ramdahl Ph.D | Self | Board Member | 000 0000 |
Clarity Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Clarity Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Clarity Pharmaceuticals FAQs
-
When was Clarity Pharmaceuticals founded?
Clarity Pharmaceuticals was founded in 2010.
-
Who is the founder of Clarity Pharmaceuticals?
Matthew Harris Ph.D and Tony Romagnino are the founders of Clarity Pharmaceuticals.
-
Who is the CEO of Clarity Pharmaceuticals?
Colin Biggin Ph.D is the CEO of Clarity Pharmaceuticals.
-
Where is Clarity Pharmaceuticals headquartered?
Clarity Pharmaceuticals is headquartered in Eveleigh, Australia.
-
What is the size of Clarity Pharmaceuticals?
Clarity Pharmaceuticals has 41 total employees.
-
What industry is Clarity Pharmaceuticals in?
Clarity Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Clarity Pharmaceuticals a private or public company?
Clarity Pharmaceuticals is a Public company.
-
What is Clarity Pharmaceuticals’s stock symbol?
The ticker symbol for Clarity Pharmaceuticals is CU6.
-
What is the current stock price of Clarity Pharmaceuticals?
As of 13-Sep-2024 the stock price of Clarity Pharmaceuticals is $5.10.
-
What is the current market cap of Clarity Pharmaceuticals?
The current market capitalization of Clarity Pharmaceuticals is $1.61B.
-
Who are Clarity Pharmaceuticals’s competitors?
Bolt Biotherapeutics, Navidea Biopharmaceuticals, Seagen, Immatics, and Kazia Therapeutics are some of the 9 competitors of Clarity Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
